Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.
Manipulation of matter
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Developing new therapies
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70% of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.
The trial is connected to the University’s ongoing work as part of the multinational consortium OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment. Funded by the U.S. Agency for International Development, OPTIMIZE is led by the Wits Reproductive Health & HIV Institute in Johannesburg, South Africa, and includes the interdisciplinary Liverpool team, Columbia University, Mylan Laboratories and the Medicines Patent Pool (MPP). OPTIMIZE is supported by key partners including UNITAID and the South African Medical Research Council (SAMRC).
Benny Kottiri, USAID’s Office of HIV/AIDS Research Division Chief, said: “The potential applications for HIV treatment are incredibly promising. By aligning efforts, these integrated investments offer the potential to reduce the doses required to control the HIV virus even further, resulting in real benefits globally. This would enable the costs of therapy to be reduced which is particularly beneficial for resource-limited countries where the burden of disease is highest.”
To watch the presentation please click here.
[osd_subscribe categories=’HIV’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “HIV”‘]
Receive an email update when we add a new HIV article.
The Latest on: HIV
via Google News
The Latest on: HIV
- Cheap Tattoos Leave 2 HIV Positive In Uttar Pradesh's Varanasion August 6, 2022 at 4:58 am
Cases of people contracting HIV after getting tattoos have emerged in Uttar Pradesh's Varanasi, prompting warnings from authorities about cheap tattoo parlours.
- Colorado teens propose addressing substance abuse, eating disorders, HIV in schoolson August 6, 2022 at 4:00 am
Teenagers from the Colorado Youth Advisory Council proposed several new state policies on Friday, including suggestions to better address substance abuse, eating disorders and HIV in schools.
- Risky stem cell transplant cures 66-year-old man of leukemia, HIVon August 6, 2022 at 2:18 am
By Sola Ogundipe After undergoing a stem celltransplant to treat leukemia, a 66-year-old man may have been cured of HIV. Known as “The City of ...
- Two people test HIV positive in Varanasi after getting tattoos, know what happenedon August 6, 2022 at 12:45 am
According to the doctors those who get tattoos should always ensure that the needle used for making the tattoo ...
- Long-lasting HIV prevention drug could be game changer — but who will pay?on August 5, 2022 at 8:26 am
Injectable antiviral cabotegravir provides stronger protection than oral pill, but researchers fear it could be too expensive to make a difference for countries with the greatest disease burden.
- New Zealand’s plan to eliminate HIV transmission ignores deepening inequities in health outcomes for Māori womenon August 4, 2022 at 1:19 pm
The omission of growing evidence that Māori, and Māori women in particular, have worse health outcomes after HIV infection could derail New Zealand’s elimination plans and exacerbate disparities.
- When HIV Stigma and Conscientious Objection Collideon August 4, 2022 at 10:16 am
The concept of conscientious objection or refusal in healthcare is not new; even the American Medical Association (AMA) supports the rights of physicians to act in accordance with conscience. But its ...
- Fauci shares the 'uh oh' moment he realized monkeypox was getting out of control in a way that is 'very reminiscent' of HIVon August 4, 2022 at 6:23 am
Dr. Anthony Fauci says the current monkeypox outbreak has been "very troublesome to me, having been there 41 years ago with HIV." ...
- HIV, STI Testing Rates Too Low in Southeast Michiganon August 4, 2022 at 6:15 am
New study findings show suboptimal HIV and sexually transmitted infection (STI) testing rates among sexual and gender minority individuals in the state, contrary to CDC guidelines.
via Bing News